Limits the use by insurers of step therapy, a protocol that establishes a specific sequence in which prescription drugs for a specified medical condition are covered by an insurer, by allowing medical providers to request step therapy exceptions.
H5119 amends Rhode Island’s Benefit Determination and Utilization Review Act and related health insurance oversight provisions to restrict how insurers use step therapy and other utilization management tools. The bill requires insurers to grant exceptions to step therapy protocols when a provider shows the required step is contraindicated, ineffective, likely ineffective, would delay or prevent medically necessary care, or would disrupt an effective drug regimen. It also sets timelines for insurers to act on exception requests, requires online submission processes, and provides that requests are presumed granted if not decided within the required time. In urgent cases, decisions must be made within 24 hours; otherwise, within 72 hours. The bill also requires insurers to use qualified healthcare professionals in reviewing exceptions and to make determinations effective for the period deemed medically necessary by the provider, up to one year.
Beyond step therapy, the bill strengthens procedural rules for utilization review and adverse benefit determinations. It requires initial, prospective, and concurrent adverse determinations to be made and signed by a licensed practitioner with the same licensure status as the ordering provider, limits retrospective denials after authorization has been granted except in specified circumstances, and requires prompt notice when claim procedures are not followed. The bill also gives the Office of the Health Insurance Commissioner explicit oversight and enforcement authority over these requirements, including the ability to require disclosures, clarify appeals procedures, limit step therapy use, and impose fines or other penalties for noncompliance.
The bill’s broader impact on state law is to expand consumer and provider protections in private health insurance coverage decisions, particularly for prescription drugs, therapies, tests, and other medically necessary services. It would affect insurers, utilization review agents, healthcare professionals, patients, and the Office of the Health Insurance Commissioner by imposing new administrative standards, response deadlines, and reporting obligations. The text also includes a wide range of existing health insurance oversight provisions, but the core operative change in this bill is the new step therapy exception framework and related enforcement authority.
Overall sentiment appears favorable toward reducing insurer barriers to care and improving access to timely treatment. The bill’s stated purpose and explanation emphasize limiting step therapy and allowing providers to obtain exceptions, suggesting support for patient access and clinical judgment. No committee transcript or vote history was provided, so there is no recorded opposition or amendment debate in the supplied materials.
The main point of contention likely concerns the balance between patient access and insurer utilization controls. Supporters would view the bill as preventing delays in medically necessary care and ensuring that treatment decisions are based on provider judgment, while insurers may object to reduced flexibility in managing costs and coverage consistency. The requirement that requests be automatically granted if deadlines are missed, along with the mandate that reviewers be healthcare professionals with relevant expertise, are likely the most significant operational and policy pressure points.
The bill would amend Rhode Island General Laws chapter 27-18.9 and chapter 42-14.5 to create enforceable step therapy exception rights, tighten utilization review procedures, and expand the Health Insurance Commissioner’s oversight and enforcement powers. It would directly affect insurers, utilization review agents, healthcare providers, and covered persons by changing how coverage denials, prior authorization, and step therapy exceptions are processed and reviewed.
The bill’s tone and explanation indicate generally supportive sentiment toward patient access, provider authority, and faster coverage decisions. Because no committee transcript or vote record was provided, there is no documented floor or committee opposition in the supplied materials, but the policy clearly favors limiting insurer control over treatment sequencing.
The likely contention is between advocates for medically necessary care and insurers concerned about cost control and utilization management. Supporters are likely to emphasize that step therapy can delay effective treatment and interfere with provider judgment, while opponents may argue that mandatory exceptions, short response deadlines, and deemed approvals reduce insurers’ ability to manage appropriate, evidence-based, and cost-effective care. The requirement that reviewers have matching licensure and expertise may also be seen as burdensome by insurers but necessary by providers and patients.